Impact of daptomycin resistance on Staphylococcus aureus virulence

Virulence

Volumn 6, Issue 2, 2015, Pages 127-131

  Cameron, David R ^a   Mortin, Lawrence I ^b   Rubio, Aileen ^b   Mylonakis, Eleftherios ^c   Moellering, Robert C ^d,e   Eliopoulos, George M ^d,e   Peleg, Anton Y ^a,d,f  

^a MONASH UNIVERSITY   (Australia)

^b CUBIST PHARMACEUTICALS INC   (United States)

^c BROWN UNIVERSITY   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f ALFRED HOSPITAL   (Australia)

Author keywords

Bacterial persistence; Galleria mellonella; MprF; S. aureus; Walk

Indexed keywords

DAPTOMYCIN; AMINOACYLTRANSFERASE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; MPRF PROTEIN, STAPHYLOCOCCUS AUREUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL VIRULENCE; GALLERIA MELLONELLA; GENE MUTATION; IMMUNE SYSTEM; INNATE IMMUNITY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PATHOGENICITY; SEPTICEMIA; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; VALIDATION PROCESS; ANIMAL; DRUG EFFECTS; GENETICS; GENOTYPE; LARVA; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOTH; MULTIDRUG RESISTANCE; PHENOTYPE; POINT MUTATION; VIRULENCE;

BACTERIA (MICROORGANISMS); GALLERIA MELLONELLA; MURINAE; STAPHYLOCOCCUS AUREUS;

AMINOACYLTRANSFERASES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOTYPE; LARVA; MICROBIAL SENSITIVITY TESTS; MOTHS; PHENOTYPE; POINT MUTATION; STAPHYLOCOCCUS AUREUS; VIRULENCE;

EID: 84926671521     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.1080/21505594.2015.1011532     Document Type: Article

References (18)

1. Fowler VG, Jr., Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65; PMID:16914701; http://dx.doi.org/10.1056?NEJMoa053783
2. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43:5285-7; PMID:16207998; http://dx.doi.org/10.1128/JCM.43.10.5285-5287.2005
3. Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, Gold HS, Baden LR, Pillai SK. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillinresistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006; 44:595-7; PMID:16455920; http://dx.doi.org/10.1128?JCM.44.2.595-597.2006
4. Ernst CM, Staubitz P, Mishra NN, Yang SJ, Hornig G, Kalbacher H, Bayer AS, Kraus D, Peschel A. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 2009; 5:e1000660; PMID:19915718; http://dx.doi.org/10.1371/journal. ppat.1000660
5. Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, Pillai S, Moellering RC, Jr., Eliopoulos GM. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 2012; 7:e28316; PMID:22238576; http:/?dx.doi.org/10.1371/journal.pone.0028316
6. Dubrac S, Msadek T. Identification of genes controlled by the essential YycG/YycF two-component system of Staphylococcus aureus. J Bacteriol 2004; 186:1175-81; PMID:14762013; http://dx.doi.org/10.1128?JB.186.4.1175-1181.2004
7. Howden BP, McEvoy CR, Allen DL, Chua K, Gao W, Harrison PF, Bell J, Coombs G, Bennett-Wood V, Porter JL, et al. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog 2011; 7:e1002359
8. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50:2137-45; PMID:16723576; http://dx.doi. org/10.1128/AAC.00039-06
9. Rubio A, Moore J, Varoglu M, Conrad M, Chu M, Shaw W, Silverman JA. LC-MS/MS characterization of phospholipid content in daptomycin-susceptible and-resistant isolates of Staphylococcus aureus with mutations in mprF. Mol Membr Biol 2012; 29:1-8; PMID:22276671; http://dx.doi.org/10.3109?09687688.2011.640948
10. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC, Jr., Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis 2009; 199:532-6; PMID:19125671; http://dx.doi.org/10.1086/596511
11. Gao W, Chua K, Davies JK, Newton HJ, Seemann T, Harrison PF, Holmes NE, Rhee HW, Hong JI, Hartland EL, et al. Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog 2010; 6:e1000944; PMID:20548948; http://dx.doi.org/10.1371/journal. ppat.1000944
12. Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45:1799-802; PMID:11353628; http://dx. doi.org/10.1128/AAC.45.6.1799-1802.2001
13. Yang SJ, Nast CC, Mishra NN, Yeaman MR, Fey PD, Bayer AS. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother 2010; 54:3079-85; PMID:20498310; http://dx.doi. org/10.1128/AAC.00122-10
14. Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, Kalbacher H, Nieuwenhuizen WF, Jung G, Tarkowski A, et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 2001; 193:1067-76; PMID:11342591; http://dx.doi. org/10.1084/jem.193.9.1067
15. Weidenmaier C, Kristian SA, Peschel A. Bacterial resistance to antimicrobial host defenses-an emerging target for novel antiinfective strategies? Current drug targets 2003; 4:643-9; PMID:14577655; http://dx.doi.org/10.2174/1389450033490731
16. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43:5285-7; PMID:16207998; http://dx.doi.org/10.1128/JCM.43.10.5285-5287.2005
17. Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, Gold HS, Baden LR, Pillai SK. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillinresistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006; 44:595-7; PMID:16455920; http://dx.doi.org/10.1128/JCM.44.2.595-597.2006
18. Gasch O, Camoez M, Dominguez MA, Padilla B, Pintado V, Almirante B, Martin C, Lopez-Medrano F, de Gopegui ER, Blanco JR, et al. Emergence of resistance to daptomycin in a cohort of patients with methicillinresistant Staphylococcus aureus persistent bacteraemia treated with daptomycin. J Antimicrob Chemother 2014; 69:568-71; PMID:24107389; http://dx.doi.org/10.1093/jac/dkt396